1. Home
  2. WAVE vs TCRX Comparison

WAVE vs TCRX Comparison

Compare WAVE & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eco Wave Power Global AB (publ)

WAVE

Eco Wave Power Global AB (publ)

HOLD

Current Price

$5.89

Market Cap

47.5M

Sector

Utilities

ML Signal

HOLD

Logo TScan Therapeutics Inc.

TCRX

TScan Therapeutics Inc.

HOLD

Current Price

$0.39

Market Cap

49.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WAVE
TCRX
Founded
2011
2018
Country
Israel
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.5M
49.4M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
WAVE
TCRX
Price
$5.89
$0.39
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.00
AVG Volume (30 Days)
9.6K
763.4K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
12.28
EPS
N/A
N/A
Revenue
N/A
$10,325,000.00
Revenue This Year
$436.84
N/A
Revenue Next Year
N/A
$19.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
266.65
52 Week Low
$4.52
$0.35
52 Week High
$10.87
$2.57

Technical Indicators

Market Signals
Indicator
WAVE
TCRX
Relative Strength Index (RSI) 37.21 16.98
Support Level $5.53 N/A
Resistance Level $6.49 $0.82
Average True Range (ATR) 0.44 0.06
MACD -0.03 -0.04
Stochastic Oscillator 28.30 4.04

Price Performance

Historical Comparison
WAVE
TCRX

About WAVE Eco Wave Power Global AB (publ)

Eco Wave Power Global AB is a Sweden-based wave energy company engaged in the development of a smart and cost-efficient wave energy conversion, or WEC, technology that converts ocean and sea waves into clean electricity. Its WEC technology employs units of point absorber floating devices, referred to as floaters, which are installed on existing marine structures such as piers, breakwaters, and jetties, or in locations in which such marine structures are required. Geographically, it has a presence in Israel, the USA, and Mexico.

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Share on Social Networks: